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ABSTRACT
Objective: The study aims at the formulation and optimization of gemfibrozil (Gem) nanosuspension (NS) for improving its solubility and dissolution rate.
Method: Gem NS was prepared by precipitation-ultrasonication method using ethanol as solvent, water as anti-solvent, and polyvinyl alcohol (PVA) 
as a stabilizer. A Box–Behnken design was employed to study the effect of the independent variables, Gem concentration in the organic phase (X1), PVA 
concentration (X2) and sonication time (X3) on the dependent variable, drug release after 90 min (Y). The resulting data were statistically analyzed and 
subjected to 3D response surface methodology to study the influence of variables on the response. NS was evaluated for particle size, zeta potential, 
solubility and in vitro drug release and characterized using Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), 
and X-ray diffractometry (XRD).
Results: On the basis of the evaluation, NS4 formulation (with 80 mg/ml Gem, 0.5% PVA concentration, and 20 min of sonication time) demonstrated 
highest drug content with a particle size of 191.0 nm and zeta potential of −12.0 mV. Dissolution profiles of NS indicated 2.5-fold increase in drug 
release than pure drug. NS demonstrated 5- and 9-fold increase in solubility, in water, and phosphate buffer (pH 7.5), respectively, pure drug. DSC and 
XRD studies indicated changes in the crystallinity of Gem during NS formulation. No chemical change was evident in NS as indicated by FTIR.
Conclusion: Gem NS formulation could serve as a promising approach for improving its solubility and dissolution rate.
Keywords: Gemfibrozil, Nanosuspension, Precipitation-ultrasonication method, Solubility enhancement, Dissolution.
INTRODUCTION
Oral delivery of drug entities is often limited due to poor drug solubility 
and lower bioavailability. More than 40% of newly discovered drugs 
are poorly soluble in water [1]. As solubility plays a crucial role in drug 
formulation, poor drug solubility has limited the commercialization of 
many drugs. Extensive efforts have been made to enhance the solubility 
of drugs by conventional methods, such as micronization [2], use of 
surfactants [3], and solubilizers [4], cosolvency [5], cocrystallization [6], 
solid dispersions [7], self micro emulsifying drug delivery systems [8], 
complexation [9], and polymorphism [10]. One of the most popular 
approaches being investigated presently is the formulation of 
nanocrystals or nanosuspension (NS). During the formulation of NS, a 
drug is reformulated and as per FDA is considered as a new drug that 
can be patented and is not considered as generic [11].
Considering the limitations of alternative approaches such as lack 
of universal applicability to all drugs as in inclusion complexes and 
microemulsion [12], nanoparticle engineering remains as a preferable 
choice for pharmaceutical application and may serve as an effective 
tool for “brick dust candidates” [13]. NS is formulated by two major 
approaches; top down and bottom up technology [14]. Top-down 
approach depends on a reduction in the size of large crystalline particles 
to the desired size range. Bottom-up approach involves solubilization of 
drug in a solvent and further addition of it to a nonsolvent to obtain 
precipitated nanocrystals under controlled conditions in the presence 
of stabilizer [15]. These technologies have been used to increase the 
solubility and bioavailability of nitrendipine [16], simvastatin [17], 
carvedilol [18], efavirenz [19], risperidone [20], etc.
Gemfibrozil (Gem) is a widely used antihyperlipidemic agent classified as 
fibric acid derivative. It increases the activity of extrahepatic lipoprotein 
lipase, resulting in the lipolysis process [21]. Gem activates peroxisome 
proliferator-activated receptor-alpha transcriptor factor ligand, a 
receptor that is involved in the metabolism of carbohydrates and fats and 
also in adipose tissue distribution [22]. This results in increased synthesis 
of lipoprotein lipase thereby increasing the clearance of triglyceride. 
Gem belongs to BCS Class II (log P 3.6) with poor solubility and high 
permeability resulting in limited and variable bioavailability [23,24].
In the present study, an attempt has been made to formulate and 
evaluate the NS of Gem using nanoprecipitation-ultrasonication 
method for improved solubility. Gem NS was evaluated for particle size, 
drug content, drug release, zeta potential, morphology, solubility, and 
in vitro drug release. NS was characterized using Fourier transform 
infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), 
and X-ray diffractometry (XRD).
MATERIALS AND METHODS
Materials
Gem was obtained from Aurobindo Pharma, Hyderabad, as a gift 
sample. Tween 20 and polyvinyl alcohol (PVA) were purchased from 
Loba Chemie, Mumbai. All the solvents and other chemicals used in the 
study were of analytical grade.
Preparation of Gem NS
Gem NS was prepared by antisolvent precipitation-ultrasonication 
method [25]. Briefly, Gem was dissolved completely in ethanol (2 ml) to 
prepare the organic phase, and the solution was then filtered through 
a 0.45 μm to remove the precipitated impurities. The antisolvent phase 
was prepared separately by dispersing stabilizer PVA in distilled water. 
At 4°C, 2 ml of organic solution was injected dropwise by syringe 
into 20 ml of antisolvent using mechanical stirrer (Remi, RQ 126 D, 
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India) at 4000 rpm for 1 h. The resultant NS was ultrasonicated with 
a probe sonicator (PCI analytics, PKS 250 F, India) at 20–25 kHz for 
different time periods. During the ultrasonication, the temperature was 
controlled at 4–8°C using ice water bath.
Optimization of NS by Box–Behnken design
Box–Behnken design was employed with 17 trial runs to study the 
impact of three factors, each at three levels, on the key response variable. 
One independent variable (X1) was Gem concentration in organic phase 
(mg/ml) at levels 20, 50, and 80 mg/ml. Second independent variable 
(X2) was PVA concentration at 0.1, 0.3, and 0.5% and third variable (X3) 
was sonication time at 10, 20, and 30 min (Table 1). The effect of these 
variables on drug release after 90 min (Y) was evaluated. The resulting 
data were fitted into Design Expert software (Stat-Ease, version 9.0, 
USA) and analyzed statistically using analysis of variance (ANOVA). 
The data were also subjected to 3D response surface methodology to 
determine the influence on the dependent variable.
To perform solid-state characterization by FTIR, DSC, and XRD; NS was 
lyophilized. Initially, and Gem NS was frozen at −20°C for 24 h followed 
by lyophilization (Labconco, FreeZone 2.5, USA).
Evaluation of Gem NS
Percent transmittance
To determine the physical stability of NS, the optical transmittance was 
measured at 600 nm using a UV spectrophotometer (Shimadzu, 1700, 
Japan).
Particle size analysis and zeta potential
The particle size analysis of NS was performed using a particle size 
analyzer (Malvern, Nano Series ZS, UK) [26]. NS was diluted with 
water and placed in the ultrasonicator bath for 5 min to prevent the 
agglomeration. All the measurements were carried out in triplicate at 
a temperature of 25°C and a fixed angle of 90°. Mean particle size and 
particle size distribution curves were recorded.
Zeta potential of Gem NS was measured using Zetasizer (Malvern, Nano 
Series ZS, UK). NS samples (1 ml) were diluted with conducting solution 
before measurements.
FTIR
Gem, its physical mixture with PVA and lyophilized Gem NS was mixed 
with potassium bromide. The FTIR spectra of these mixtures were 
recorded using a FTIR spectrometer (Shimadzu, 8400S, Japan) with 
DRS attachment [27].
DSC
The physical state of Gem in lyophilized NS was characterized by DSC 
thermogram analysis. The DSC patterns of Gem, its physical mixture 
with PVA and NS was recorded (PerkinElmer, 4000, UK). Sample 
analysis was performed in an aluminum pan, under nitrogen Purging 
with a flow rate of 20 ml/min and heating range as 30–300°C with a 
rate of heating, 10°C/min [28].
Table 1: Data for independent variables and response for Box–Behnken design
Batch 
code
Factor X1: Gem 
concentration in organic 
phase (mg/ml)













NS1 20 0.1 20 81.3±3.2 72.2±1.2 (+)
NS2 80 0.1 20 86.2±1.0 43.7±2.7 (−)
NS3 20 0.5 20 89.8±2.4 93.5±0.5 (+)
NS4 80 0.5 20 96.2±1.9 87.3±3.1 (++)
NS5 20 0.3 10 86.5±2.0 90.7±4.1 (−)
NS6 80 0.3 10 85.4±3.6 80.0±2.6 (−)
NS7 20 0.3 30 87.2±1.9 94.1±3.8 (+)
NS8 80 0.3 30 80.1±2.6 82.7±0.9 (+)
NS9 50 0.1 10 74.2±4.1 63.8±1.3 (−)
NS10 50 0.5 10 79.1±2.1 76.6±2.9 (−)
NS11 50 0.1 30 76.7±3.1 88.8±3.4 (+)
NS12 50 0.5 30 82.0±2.5 96.2±1.9 (++)
NS13 50 0.3 20 80.2±1.2 87.0±2.7 (+)
NS14 50 0.3 20 81.3±2.5 84.2±1.7 (+)
NS15 50 0.3 20 80.6±1.5 89.1±3.3 (+)
NS16 50 0.3 20 82.3±2.1 87.6±2.0 (+)
NS17 50 0.3 20 81.6±2.0 85.9±3.2 (+)
*Mean±SD (n=3), **Stability after 24 h, (−) high precipitation, (+) low precipitation, (++) opalescent and stable. SD: Standard deviation, PVA: Polyvinyl alcohol, NS: 
Nanosuspension
Table 2: Data of ANOVA analysis for Gem NS
Source Sum of squares df Mean square F value p value
Prob>F
Model 356.39 9 39.60 3.93 0.0424 significant
X1: Gem concentration 1.19 1 1.19 0.12 0.7409
X2: PVA concentration 102.82 1 102.82 10.20 0.0152
X3: Sonication time 0.056 1 0.056 0.055 0.9426
X1 X2 0.59 1 0.59 0.06 0.8153
X1 X3 9.33 1 9.33 0.93 0.3680
X2 X3 0.053 1 0.053 0.052 0.9443
X12 203.36 1 203.36 20.17 0.0028
X22 0.14 1 0.14 0.014 0.9095
X32 48.11 1 48.11 4.77 0.0652
df: degrees of freedom, PVA: Polyvinyl alcohol, NS: Nanosuspension, Gem: Gemfibrozil
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XRD
XRD study was performed in X-ray diffractometer (Brucker, D 8 
advanced, India) using Cu K 2α rays with a voltage of 40 kV and a 
current of 25 mA to estimate the effect on the crystalline structure of 
lyophilized NS. Samples were scanned for 2Ɵ from 10 to 80°. Diffraction 
pattern for pure Gem, physical mixture and NS were analyzed [29].
Drug content
For determination of drug content, NS was centrifuged at 300 rpm for 5 
to 10 min to remove the precipitated drug. After removal of precipitate, 
1 mL of NS was taken and diluted with methanol. The absorbance was 
taken at 276 nm in a UV spectrophotometer (Shimadzu, 1700, Japan) 
and drug concentration was determined by a standard curve of the drug 
in methanol [30].
In vitro drug release
The dissolution of Gem from pure drug and NS was performed using 
modified dissolution assembly, USP apparatus type I (Veego, DT60, India) 
by dialysis method [31]. The dialysis bag (mol wt cutoff, 11 KDa) was 
soaked overnight in dissolution medium before dialysis to ensure thorough 
wetting of the membrane. Dissolution medium used was 7.5 pH phosphate 
buffer. Pure drug and equivalent quantity of NS were placed in dialysis bags, 
and the closed ends of bags were tied to basket shaft. The shaft with bag 
was then inserted into the dissolution medium containing 100 ml of 7.5 pH 
phosphate buffer at 37±0.5°C and dissolution was performed with stirring 
speed of 50 rpm for 90 min. An aliquot of 5 ml was withdrawn at an interval 
of 15 min, suitably diluted, filtered, and analyzed for the content of Gem 
by UV-spectrophotometer (Shimadzu, 1700, Japan) at 276.0 nm. Aliquot 
was replaced with an equivalent volume of fresh dissolution medium to 
compensate for the loss due to sampling. The cumulative drug release for 
pure drug and NS formulation was calculated and compared for 90 min.
Saturation solubility study
The saturation solubility of pure Gem and lyophilized Gem NS was 
determined in water and phosphate buffer pH 7.5 [32]. Excess amounts 
of samples were added into 10 ml solvent in a capped vial which was then 
placed in a controlled temperature shaking water bath at 37°C, leaving 
them to dissolve for 72 h. Then, samples (1 ml) were withdrawn and 
centrifuged at 3000 rpm for 20 min. The obtained supernatant sample 
was assayed using a UV-Visible spectrophotometer (Shimadzu, UV-1700, 
Japan) at 276 nm [33,34]. The experiment was conducted in triplicate.
RESULTS
Effect of independent variables on drug release
The results of the dependent variable, drug release after 90 min (Y) 
from 17 experiments is shown in Table 1. Equation 1 was obtained from 
multiple linear regression analysis of data.
Drug release after 90 min (Y)=81.26+0.39 X1+3.58 X2+0.084X3+ 
0.39X1X2−1.53X1X3+0.12X2X3+6.95X12+0.18X22−3.38X32 (1)
To study the significance of regression coefficients, ANOVA was followed 
by student t-test. Table 2 indicates data of ANOVA analysis.
The drug content of NS formulation was found to be in the range of 
43.7–96.2%. During optimization, formulations with high drug loading 
and low precipitation (+) or opalescent appearance (++) after 24 h were 
considered.
Fig. 1 shows the effect of PVA concentration and Gem concentration 
on drug release. Fig. 2 indicates the influence of Gem concentration 
and sonication time on the drug release from NS formulations. Fig. 3 
indicates the effect of PVA concentration and sonication time on the 
drug release from NS formulation.
Particle size and zeta potential
The particle size of NS formulation (NS4) was found to be 191.0 nm 
with a polydispersity index (PDI) of 0.28 (Fig. 4). The zeta potential of 
NS formulation was found to be −12.0 mV (Fig. 5).
Infrared spectroscopy
To observe any major chemical change after formulation of NS, FTIR 
analysis of Gem, its physical mixture with PVA as stabilizer and NS 
formulation was carried out and shown in Fig. 6.
DSC
Fig. 7 indicates DSC of Gem, its physical mixture with PVA and 
lyophilized NS formulation.
XRD
To study the changes occurred in crystallinity of Gem during formulation 
of NS, XRD study was carried out. Fig. 8 indicates a XRD pattern of Gem, 
physical mixture of Gem and PVA and lyophilized NS formulation.
In vitro drug release
The in vitro drug release studies of NS formulation and Gem pure drug 
was carried out in USP type I apparatus using dialysis bag method in 
Fig. 1: (a) Counterplot (b) response surface plot showing the 
influence of gemfibrozil concentration and polyvinyl alcohol 
concentration on the drug release from nanosuspension
Fig. 2: (a) Counterplot (b) response surface plot showing the 
influence of gemfibrozil concentration and sonication time on the 
drug release from nanosuspension formulations
Fig. 3: (a) Counterplot (b) response surface plot showing the 
influence of polyvinyl alcohol concentration and sonication time 
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phosphate buffer pH 7.5. The drug release profile of the optimized Gem 
NS (NS4) and Gem pure drug is shown in Fig. 9.
Saturation solubility
The solubility of optimized NS formulation, NS4, and pure Gem was 
carried out in water and in phosphate buffer pH 7.5 (Fig. 10).
DISCUSSION
Effect of independent variables on drug release
For optimization of formulation variables for Gem NS, Box–Behnken 
design was applied with 17 trial runs. The data from Table 1 were 
used to generate a quadratic equation from “Design Expert 9.0”. 
Mathematical relationship was generated using MLRA for the studied 
response variable (Equation 1).
The significant test for regression coefficients was carried out by 
applying a student t-test. If p>F values were >0.05, the coefficients were 
not considered as significant. The lower value of p>F (0.042) indicated 
the significance of applied model (Table 2). From ANOVA data, it was 
observed that the effect of PVA concentration was significant on drug 
release. This was evident from p>F value <0.05 and higher F value 
Fig. 4: Particle size analysis of gemfibrozil nanosuspension
Fig. 5: Zeta potential analysis of gemfibrozil nanosuspension
Fig. 6: Infrared spectroscopy of (a) pure gemfibrozil (Gem), 
(b) physical mixture, and (c) Gem nanosuspension formulation
Fig. 7: Differential scanning calorimetry of (a) pure gemfibrozil 
(Gem), (b) physical mixture, and (c) Gem nanosuspension 
formulation
Fig. 8: X-ray diffraction of (a) pure gemfibrozil (Gem), (b) physical 
mixture, and (c) Gem nanosuspension formulation
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(10.2). Higher values of p>F in case of independent variables, Gem 
concentration (X1) and sonication time (X3) indicated that the effect of 
these variables on drug release was not significant. Higher values of p>F 
for interactive terms of variables (X1 X2, X1 X3, and X2 X3) indicated that 
there was no interactive effect of independent variables. Lower value of 
p>F (0.0028) for the quadratic term (X12) indicated the nonlinear effect 
Gem concentration.
Influence of Gem concentration and PVA concentration on the drug 
release
With the increase in drug concentration in organic phase from 20 to 
50 mg/ml, drug release was found to be decreased (Fig. 1). This could 
be due to increase in particle size of NS with increase in the drug 
concentration leading to lower surface area and lower drug release. 
With further increase in drug concentration from 50 to 80 mg/ml, 
drug release was found to be increased. At higher drug concentration, 
the degree of supersaturation was high. This increased the rate 
of precipitation at a faster rate. The drug was precipitated out in 
amorphous form resulting in higher drug release.
Increase in PVA concentration was found to be increasing the drug 
release. This effect was pronounced at higher drug concentration. This 
could be attributed to the ability of PVA to form a coat around the crystal 
nuclei and retarding the excess growth of crystals. Gem has –COOH 
group that can form hydrogen bonds with hydrophilic PVA. This helps 
PVA to approach easily to growing crystal nuclei and thus controlling 
the size of drug crystal. Lower particle size could have resulted in an 
increase in drug release.
Influence of Gem concentration and sonication time on drug 
release
From Fig. 2, it is evident that with an increase in drug concentration 
from 20 to 50 mg/ml, at lower sonication time (10 min), drug release 
was found to be decreased. With further increase in drug concentration 
from 50 to 80 mg/ml, drug release was found to be increased.
It was observed that the increase in sonication time resulted in increased 
drug release from NS. This could be due to a decrease in particle size 
with increased sonication that might have led to increased surface area 
resulting in increased drug release. At higher drug concentration, the 
effect of sonication time was not significant, and lower particle size was 
not achieved.
Influence of PVA concentration and sonication time on drug 
release
From Fig. 3, it was observed that with an increase in PVA concentration, 
drug release was found to be increased at all levels of sonication time. 
At all levels of PVA concentration, increase in sonication time from 10 
to 20 min, increased the drug release, however, with further increase in 
sonication time to 30 min, decreased the drug release. This could be due 
to the agglomeration of particles due to excessive sonication. Increase 
in sonication increases the free energy of the system drastically, thus, 
resulting in thermodynamic instability in NS.
Particle size and zeta potential
As the physical stability of NS depends on particle size, lower size 
(191.0 nm) may lead to greater stability of NS. PDI is a measure of 
particle size distribution. Lower values of PDI (0.28) indicated narrower 
particle size distribution resulting in greater physical stability.
Zeta potential is a measure of surface charge on particles. Higher zeta 
potential values indicate lower agglomeration and greater stability 
in a colloidal dispersion. Slightly lower values of the zeta potential of 
NS (−12.0 mV) could be attributed to nonionic stabilizer PVA forming 
a coat around nanoparticle of Gem. This nonionic coat is responsible 
for the formation of the solvent sheath around the particle rendering 
additional stability to NS.
Infrared spectroscopy
The characteristic absorption peak for Gem was observed as –C-H 
stretch at 3045.70/cm, -C=O stretch at 1836.28/cm, and -C-O stretch 
at 1049.31/cm, respectively (Fig. 6). FTIR of a physical mixture or NS 
revealed no major shift at the wavelengths when compared to FTIR 
of Gem. This indicated that no chemical change was occurred in the 
formulation during NS formulation.
DSC
DSC studies of drug exhibited a sharp peak at 60.8°C which indicates 
the melting point of Gem. The presence of a sharp peak indicates 
the crystalline nature of the drug. DSC of physical mixture and NS 
formulation showed an endothermic peak at 221.9°C indicating the 
presence of PVA. DSC of physical mixture retained the endotherm 
of the drug. DSC of formulation indicated a very small peak at 55.4°C 
representing a major change in crystallization of Gem during NS 
formulation. The presence of small and wide endothermic peak 
confirms conversion of Gem to amorphous form.
XRD
XRD pattern of pure Gem indicated intense peaks at 11.5, 11.6, and 
11.9° which were characteristic of pure drug Gem. These intense peaks 
indicated the crystalline nature of the drug. XRD of physical mixture 
retained an intense peak of Gem and also showed additional intense 
peaks at 18.3, 24.2, and 24.30° representing the presence of PVA. XRD 
of formulation indicated a significant reduction in the intensity of Gem 
peaks at 11.5, 11.5, and 11.9°. This could be due to partial amorphization 
of the drug during the process of NS. As the intensity of peak was not 
completely masked, there was the possibility of the presence of drug in 
nanocrystalline form.
In vitro drug release
The drug release from NS formulation was found to follow biphasic 
release pattern; initial burst release followed by sustained drug release 
over 90 min of dissolution study. Initial burst release is due to small 
sized amorphous particles and crystal nuclei. Slow drug release could 
be due to agglomerated particles found during the process.
Fig. 9: Comparative in vitro drug release profile of nanosuspension 
and pure gemfibrozil. *Mean±standard deviation (n=3)
Fig. 10: Saturation solubility of pure gemfibrozil and 
nanosuspension formulation. *Mean±standard deviation (n=3)
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Drug release from NS4 formulation was found to be highest than other 
formulations. NS4 formulation released 57.2±1.5% after 15 min of 
dissolution and 96.2±1.72% after 90 min of dissolution. The drug content 
and physical stability of this formulation were high. When dissolution 
profile of pure drug was compared with NS4 formulation (Fig. 9), it was 
observed that there was 2.5-fold increase in drug release after 15 min 
of dissolution whereas after 90 min of dissolution there was 1.5-fold 
increase in drug release. This could be due to change in crystallinity of 
drug during NS process. During the NS preparation, Gem was dissolved 
in ethanol and was further precipitated out in antisolvent in the presence 
of stabilizer which could have changed the drug from crystalline to 
amorphous form. This was in agreement with the DSC and XRD results.
Saturation solubility
Formulated Gem NS showed high solubility in water as compared to the 
pure drug (Fig. 10). The increase in solubility was approximately 5- and 
9-fold in water and phosphate buffer, respectively. This was attributed 
to a reduction in particle size and transition to an amorphous state of 
the drug during NS formulation.
CONCLUSION
Gem NS was successfully prepared by a precipitation-ultrasonication 
method with a lower particle size (191.0 nm) and narrow size 
distribution. A change in drug crystallinity during NS formulation was 
evident from DSC and XRD study. FTIR revealed no chemical change 
in NS formulation. Gem NS exhibited markedly enhanced solubility 
and dissolution rate compared to pure drug. The present study 
demonstrated NS as a potential drug delivery system for improving 
solubility and dissolution rate of the poorly soluble drug.
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